Recent reports suggested that direct acting antivirals (DAAs) might favor hepatocellular carcinoma (HCC). In study 1, we studied the proangiogenic liver microenvironment in 242 DAA‐treated chronic hepatitis C patients with advanced fibrosis. Angiopoietin‐2 (ANGPT2) expression was studied in tissue (cirrhotic and/or neoplastic) from recurrent, de novo, nonrecurrent HCC, or patients never developing HCC. Circulating ANGPT2,vascular endothelial growth factor (VEGF), and C‐reactive protein (CRP) were also measured. In study 2, we searched for factors associated with de novo HCC in 257 patients with cirrhosis of different etiologies enrolled in a dedicated prospective study. Thorough biochemical, clinical, hemodynamic, endoscopic, elastographic, and echo‐Doppler work‐up was performed in both studies. In study 1, no patients without cirrhosis developed HCC. Of 183 patients with cirrhosis, 14 of 28 (50.0%) with previous HCC recurred whereas 21 of 155 (13.5%) developed de novo HCC. Patients with recurrent and de novo HCCs had significantly higher liver fibrosis (LF) scores, portal pressure, and systemic inflammation than nonrecurrent HCC or patients never developing HCC. In recurrent/de novo HCC patients, tumor and nontumor ANGPT2 showed an inverse relationship with portal vein velocity (PVv; r = –0.412, P = 0.037 and r = –0.409, P = 0.047 respectively) and a positive relationship with liver stiffness (r = 0.526, P = 0.007; r = 0.525, P = 0.003 respectively). Baseline circulating VEGF and cirrhotic liver ANGPT2 were significantly related (r = 0.414, P = 0.044). VEGF increased during DAAs, remaining stably elevated at 3‐month follow‐up, when it significantly related with serum ANGPT2 (r = 0.531, P = 0.005). ANGPT2 expression in the primary tumor or in cirrhotic tissue before DAAs was independently related with risk of HCC recurrence (odds ratio [OR], 1.137; 95% confidence interval [CI], 1.044‐1.137; P = 0.003) or occurrence (OR, 1.604; 95% CI, 1.080‐2.382; P = 0.019). In study 2, DAA treatment (OR, 4.770; 95% CI, 1.395‐16.316; P = 0.013) and large varices (OR, 3.857; 95% CI, 1.127‐13.203; P = 0.032) were independent predictors of de novo HCC. Conclusion: Our study indicates that DAA‐mediated increase of VEGF favors HCC recurrence/occurrence in susceptible patients, that is, those with more severe fibrosis and splanchnic collateralization, who already have abnormal activation in liver tissues of neo‐angiogenetic pathways, as shown by increased ANGPT2. (Hepatology 2018; 00:000‐000).
Alpha-interferon (IFN-alpha) is an effective treatment for chronic hepatitis C, but only 20% to 30% of patients are apparently cured with the current recommended schedule of 3 MU given three times a week for 6 months. To evaluate the efficacy of more aggressive treatment regimens, we have conducted a randomized trial in 174 patients with chronic hepatitis C using three different schedules: (1) 12-month treatment starting with 6 MU/ three times a week and decreasing the dose on the basis of serum alanine transaminase (ALT) activities (group A: 59 cases); (2) fixed dose of 3 MU three times a week for 12 months (Group B: 61 cases), (3) fixed dose of 6 MU three times of week for 6 months (Group C: 54 cases). Patients were evaluated during therapy for biochemical and virological response and followed for at least 12 months after therapy to assess long-term efficacy and liver histological outcome. The genotype of infecting HCV was also analyzed in all patients, and predictors of response were determined by multivariate analysis. Serum ALT became normal during therapy in 76% of patients (95% confidence interval [CI]: 63 to 86), 65% (CI: 52 to 77), and 74% (CI: 60 to 85) in groups A, B, and C, respectively (P = NS). The corresponding figures for sustained response 12 months after therapy were 49% (CI: 36 to 62), 31% (CI: 20 to 44), and 28% (CI: 16 to 42)(A vs. B, P = .06; A vs. C, P = 0.03). Eighty-six percent of patients with sustained response cleared HCV-RNA from serum, and 72% improved histologically.(ABSTRACT TRUNCATED AT 250 WORDS)
About 3-4% of cirrhotic patients develop primary liver cancer every year. Specific serologic markers have not yet been identified for screening of high risk patients. The serpin squamous cell carcinoma antigen (SCCA) is overexpressed in liver cancer and circulating SCCA-IgM complexes have been described in patients with hepatocellular carcinoma (HCC). The aim of the present study was to assess the behavior of SCCA-IgM in relation to HCC development in patients with cirrhosis. A retrospective, longitudinal study was conducted in a cohort of prospectively followed cirrhotic patients. Two groups with similar clinical profile at presentation were studied : group A included 16 patients who developed HCC during a median follow up of 4 years; group B included 17 patients who did not develop HCC during the same time interval. Circulating SCCA-IgM immune complexes were determined using a recently standardized ELISA assay. At presentation similar levels of SCCA-IgM complexes [mean 6 SD: 267.40 6 382.25 U/ml vs. 249.10 6 446.90 U/ml, p 5 0.9006] and of alpha-fetoprotein [AFP; 24.11 6 59.04 IU/ml vs. 10.91 6 23.34 IU/ml, p 5 0.3995] were detected in group A and in group B. The increase over time (/) of SCCA-IgM, assessed within at least one year before clinical diagnosis of HCC, was remarkably higher in group A than in group B (mean 6 SD 5 280.05 6 606.71 (U/ml)/year vs. 237.92 6 95.94 (U/ml)/year, p 5 0.0408), while AFP increase was not significantly different (11.89 6 23.27 (IU/ml)/year vs. 3.67 6 11.46 (IU/ ml)/year, p 5 0.2179). Receiver operating characteristic (ROC) curves were plotted for the rate of change in the levels of both markers and the diagnostic accuracy measured as AUROC was higher for SCCA-IgM / (0.821) than for AFP / (0.654). In conclusion, the progressive increase of SCCA-IgM over time was associated with liver tumor development, suggesting that monitoring the behavior of SCCA-IgM might become useful to identify cirrhotic patients at higher risk of HCC development. ' 2006 Wiley-Liss, Inc.Key words: SCCA-IgM; hepatocellular carcinoma; serologic prognostic marker; cirrhosis Hepatocellular carcinoma (HCC) is one of the major health problems worldwide, due to its high incidence and severe prognosis. Figures depicting half a million new cases per year have been reported, and projection studies have estimated an increase of tumor development within the next decade in developed countries. 1The reasons advocated to explain this phenomenon are the increased rate of HCV infection and an improvement in clinical management of liver cirrhosis, identified as the major risk factor for HCC development.2 About 3-4% of cirrhotic patients develop primary liver cancer every year and this justifies surveillance programs to detect HCC at an early stage. 3 The prognosis of the patients depends mainly on the evolutionary stage of the neoplasm, ranging from 5-years survival higher than 70% in surgical patients to less than 3 months in very advanced tumors. 4 Tumor size is one of the main factors influencing the possibility of b...
The long-term benefit of interferon therapy in chronic hepa-at the end of the first course of treatment. (HEPATOLOGY 1997;26(Suppl 1):137S-142S.) titis C is limited. During therapy, serum alanine aminotransferase (ALT) levels decrease to normal and hepatitis C virus (HCV) RNA decreases in 40% to 60% of patients. However, Chronic hepatitis C is a common disease worldwide and most patients relapse after therapy withdrawal, so that no is the major cause of chronic liver disease, cirrhosis, and more than 15% to 25% achieve a sustained response. Re-hepatocellular carcinoma in many countries. The disease oftreatment has been evaluated in studies using different regi-ten remains asymptomatic for a prolonged period, but cirrhomens and forms of alpha interferon in different cohorts of sis develops insidiously in at least 20% to 30% of chronically patients at different times after initial therapy. Both end-of-infected individuals.1 Current therapies for chronic hepatitis treatment and sustained responses to re-treatment correlate C are rather unsatisfactory. Various forms of alpha interferon with the type of response achieved during the initial course. are the standard therapy for the disease, having been proven Patients who do not respond or have only a partial response to be efficacious in several large randomized trials. A 6-to the initial course of interferon have an extremely low rate month course of alpha interferon leads to a normalization of of sustained response when re-treated, independently of the alanine aminotransferase (ALT) levels and suppression of regimen used. Combining data from 13 studies, sustained hepatitis C virus (HCV) RNA levels in approximately 40% to responses occurred in no patients who were re-treated with 60% of patients, but these effects are sustained after therapy 3 million units (MU) three times weekly for 6 months, and withdrawal in no more than 50% of the initial responders. 2,3 in only 2% to 3% of patients re-treated with higher doses and/ Several studies have now shown that the rate of sustained or for longer periods. In contrast, a significant number of response can be improved by using a higher dose of interpatients who responded during the initial course but subse-feron and/or a long duration of treatment.4,5 However, these quently relapsed have a sustained response when re-treated regimens are associated with more side effects and higher with interferon alone. Combining data from 11 published costs and, in most studies, have shown only a limited advanstudies on patients who relapsed after an initial course, sus-tage over the standard schedule, with rates of sustained retained responses occurred in 15% (95% confidence interval sponse improving by only 10% to 15%. For these reasons, [CI], 10%-20%) of patients re-treated with 3 MU three times there is still controversy regarding the optimal regimen for weekly for 6 months, in 29% (CI, 17%-40%) re-treated with alpha interferon therapy of chronic hepatitis C. a higher dose for 6 months, and in 43% (CI, 34%-50%) re-The observation that...
ObjectiveThe benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.DesignWe pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson.ResultsRecurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1).ConclusionEffects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.